行情

CRMD

CRMD

CORMEDIX
NASDAQ

实时行情|Nasdaq Last Sale

7.85
-0.29
-3.56%
盘后: 7.88 +0.03 +0.38% 17:06 06/17 EDT
开盘
8.06
昨收
8.14
最高
8.25
最低
7.69
成交量
32.19万
成交额
--
52周最高
18.80
52周最低
3.860
市值
2.99亿
市盈率(TTM)
-10.4098
分时
5日
1月
3月
1年
5年
每日生物技术动向：辉瑞-BioNTech COVID-19订单流比比皆是，CMO Voyager首席执行官离任，Bristol-Myers Squibb的决策日，ASCO摘要移动股票
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19)
Benzinga · 05/20 12:27
74从星期五起最大动作
Gainers MoSys, Inc. (NASDAQ: MOSY) shares climbed 50.5% to settle at $4.35 on Friday. MoSys, last week, reported a loss for its first quarter.
Benzinga · 05/17 09:21
午后市场动态：道琼斯指数上涨400点； CorMedix分享幻灯片
Toward the end of trading Friday, the Dow traded up 1.19% to 34,424.80 while the NASDAQ rose 2.41% to 13,440.75. The S&P also rose, gaining 1.62% to 4,179.15.
Benzinga · 05/14 19:09
午盘市场更新：原油上涨2％；原油上涨2％。第一季度业绩公布后，CorMedix股票下跌
Midway through trading Friday, the Dow traded up 0.85% to 34,310.56 while the NASDAQ rose 1.88% to 13,371.18. The S&P also rose, gaining 1.26% to 4,164.50.
Benzinga · 05/14 16:10
周五中盘时段有54只股票在移动
Gainers HyreCar Inc. (NASDAQ: HYRE) shares jumped 44.5% to $12.93 after the company reported Q1 results.
Benzinga · 05/14 16:02
为什么Bionano Genomics，CorMedix和Eloxx周五要搬迁
Bionano Genomics, Inc. (NASDAQ: BNGO), CorMedix Inc. (NASDAQ: CRMD) and Eloxx Pharmaceuticals, Inc.
Benzinga · 05/14 14:27
周五盘前交易中的12种医疗保健股
 
Benzinga · 05/14 12:18
每日生物技术动向：由于DefenCath NDA的重新提交延迟，CorMedix下滑，Apellis等待FDA决定，Vera Therapeutics首次亮相
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 05/14 11:59
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解CRMD最新的财务预测，通过CRMD每股收益，每股净资产，每股现金流等数据分析CORMEDIX近期的经营情况，然后做出明智的投资选择。
分析师评级

5位分析师的综合评级

买入

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测CRMD价格均价为20.30，最高价位29.00，最低价为10.00。
EPS
机构持股
总机构数: 94
机构持股: 1,193.75万
持股比例: 31.37%
总股本: 3,805.37万
类型机构数股数
增持
26
143.28万
建仓
16
100.21万
减持
21
44.80万
平仓
12
46.54万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
+0.12%
制药与医学研究
+0.27%
高管信息
Non-Executive Chairman/Independent Director
Myron Kaplan
Chief Executive Officer/Director
Khoso Baluch
Chief Financial Officer/Executive Vice President
Matt David
Chief Financial Officer/Executive Vice President
Matthew David
Executive Vice President/General Counsel
Phoebe Mounts
Executive Vice President
John Armstrong
Executive Vice President
Elizabeth Masson
Executive Vice President
Elizabeth Masson Hurlburt
Other
Thomas Nusbickel
Independent Director
Paulo Costa
Independent Director
Janet Dillione
Independent Director
Gregory Duncan
Independent Director
Alan Dunton
Independent Director
Steven Lefkowitz
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
CRMD 简况
CorMedix Inc. is a commercial pharmaceutical and medical device company. The Company in-licenses, develops and commercializes prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company has in-licensed the rights to develop and commercialize its product candidate, CRMD003 (Neutrolin), which addresses market opportunities in the instances in which a central venous catheter is used, such as hemodialysis, intensive care units, oncology, and patients receiving total parenteral nutrition, intravenous (IV) hydration, and/or IV medications. Neutrolin is an anti-infective solution for the prevention of catheter-related infections and thrombosis in the central venous catheter markets, such as dialysis, critical care and oncology. Neutrolin is a broad-spectrum antimicrobial/antifungal and anticoagulant combination that is active against common microbes, including antibiotic-resistant strains, and may prevent biofilm formation.

微牛提供CorMedix Inc.(NASDAQ-CRMD)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CRMD股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CRMD股票基本功能。